Polymorphisms of GST genes were promising candidate biomarkers for evaluating the AML risk, which may also affect the treatment of leukemia, as GSTs have a role in detoxifying active metabolites of cytotoxic chemotherapeutic agents [29]. The gene discussed is HPGDS; the disease is acute myeloid leukemia.